

Fee Calculation:

Prior to this amendment, the previously paid claim fee included the fee for 9 total claims and 2 independent claims. Upon entry of the amendment there will 9 total claims and 2 independent claims. Hence, there is no an additional claim fee owing due to this amendment.

Summary of Claim Amendments

Claims 51-59 were pending prior to this amendment.

Claims 51-55 and 56-59 are rejected as obvious under 35 USC 103 over Pathak (US 6,113,944) in combination with Benneker (US 5,874,447) and Takedo (US 5,486,365).

Claim 56-58 are rejected under 35 USC 112 due to confusion in the claims over the lower limit of the water content.

Claim 56 is amended.

Claims 51-59 are presented for reconsideration.

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-50. Cancelled.

51. (Previously Presented). A pharmaceutical composition comprising a sulfonate salt of paroxetine, calcium hydrogen phosphate anhydrate, a disintegrant and a lubricant, wherein said composition does not contain lactose or microcrystalline cellulose.

52. (Previously Presented). The composition according to claim 51, wherein said composition does not contain a hydrosoluble or hydrophilic diluent.

53. (Previously Presented). The composition according to claim 51, wherein said contains said calcium hydrogen phosphate anhydrate as the only diluent.

54. (Previously Presented). The composition according to claim 51, wherein said sulfonate salt of paroxetine is paroxetine methane sulfonate.

55. (Previously Presented). The composition according to claim 51, which consists essentially of paroxetine methane sulfonate, calcium hydrogen phosphate anhydrate, sodium starch glycolate, and magnesium stearate.

56. (Currently Amended). A pharmaceutical composition comprising a sulfonate salt of paroxetine, calcium hydrogen phosphate anhydrate, a disintegrant and a lubricant, wherein said composition has a pH within the range of 5.0 to 6.0 and said composition has an added water content of 1.2 wt% or less.

57. (Previously Presented)). The pharmaceutical composition according to claim 56, which has an added water content of 0 to 1.0 wt%.

58. (Previously Presented). The composition according to claim 56, which has an added water content of 0 to 0.8 wt\$.

59. (Previously Presented). The composition according to claim 56, wherein said sulfonate salt is paroxetine methane sulfonate.